Novel aspects concerning the functional cross-talk between the insulin/IGF-I system and estrogen signaling in cancer cells

Frontiers in Endocrinology

Volumn 6, Issue MAR, 2015, Pages

  De Marco, Paola ^a   Cirillo, Francesca ^a   Vivacqua, Adele ^a   Malaguarnera, Roberta ^b   Belfiore, Antonino ^a,b   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer cells; Cancer associated fibroblasts; Estrogen receptor; GPR30 GPER; Insulin IGF system; Signal transduction

Indexed keywords

CBL PROTEIN; CYCLIC AMP; CYCLIN A; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; GLUCOSE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INSULIN RECEPTOR SUBSTRATE 3; INSULIN RECEPTOR SUBSTRATE 4; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROINSULIN; PROTEIN KINASE B; PROTEIN P85; PROTEIN SHC; RAS PROTEIN; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HYPERINSULINEMIA; KIDNEY DISEASE; METABOLIC SYNDROME X; METASTASIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN FUNCTION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84926667645     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00030     Document Type: Short Survey

References (123)

1. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev (1996) 76:1005-26.
2. Hernandez-Sanchez C, Mansilla A, de la Rosa EJ, de Pablo F. Proinsulin in development: new roles for an ancient prohormone. Diabetologia (2006) 49:1142-50. doi: 10.1007/s00125-006-0232-5
3. Holly JMP, Perks CM. Insulin-like growth factor physiology: what we have learned from human studies. Endocrinol Metab Clin North Am (2012) 41:249-63. doi:10.1016/j.ecl.2012.04.009
4. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal (2011) 23:1515-27. doi:10.1016/j.cellsig.2011.05.004
5. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 30:586-623. doi:10.1210/er.2008-0047
6. Ahmad T, Farnie G, Bundred NJ, Anderson NG. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem (2004) 279:1713-9. doi:10.1074/jbc.M306156200
7. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev (2004) 18:1926-45. doi:10.1101/gad.1212704
8. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2007) 28:20-47. doi:10.1210/er.2006-0001
9. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-1 receptors in human cancer. Curr Pharm Des (2007) 13:671-86. doi:10.2174/138161207780249173
10. Aiello A, Pandini G, Sarfstein R, Werner H, Manfioletti G, Vigneri R, et al. HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer (2010) 46:1919-26. doi:10.1016/j.ejca.2010.02.050
11. Pandini G, Medico E, Conte E, Sciacca L, Vigneri R, Belfiore A. Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J Biol Chem (2003) 278:42178-89. doi:10.1074/jbc.M304980200
12. Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie (1999) 81:403-7. doi:10.1016/S0300-9084(99)80088-1
13. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest (1990) 86:1503-10. doi:10.1172/JCI114868
14. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999) 5:1935-44.
15. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther (2010) 9:2652-64. doi:10.1158/1535-7163.MCT-10-0318
16. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev (2003) 12:84-9. Available from: http://cebp.aacrjournals.org/content/12/2/84.long
17. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol (2004) 22:3104-12. doi:10.1200/JCO.2004.10.105
18. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 351:1393-6. doi:10.1016/S0140-6736(97)10384-1
19. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 19:3278-88.
20. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene (1999) 18:2471-9. doi:10.1038/sj.onc.1202600
21. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, et al. The IGF system in thyroid cancer: new concepts. Mol Pathol (2001) 54:121-4. doi:10.1136/mp.54.3.121
22. Sacco A, Morcavallo A, Pandini G, Vigneri R, Belfiore A. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology (2009) 150:3594-602. doi:10.1210/en.2009-0377
23. Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, Belfiore A. Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology (2012) 153(5):2152-63. doi:10.1210/en.2011-1843
24. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 87:245-54. doi:10.1210/jcem.87.1.8142
25. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology (2003) 144:2650-8. doi:10.1210/en.2002-0136
26. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 68:10238-46. doi:10.1158/0008-5472.CAN-08-2755
27. Sarfstein R, Pasmanik-Chor M, Yeheskel A, Edry L, Shomron N, Warman N, et al. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem (2012) 287:2766-76. doi:10.1074/jbc.M111.281782
28. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem (2008) 114:63-70. doi:10.1080/13813450801954451
29. Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer (2012) 19:R225-41. doi:10.1530/ERC-12-0203
30. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer (2009) 125:2704-10. doi:10.1002/ijc.24609
31. Catsburg C, Gunter MJ, Chen C, Cote ML, Kabat GC, Nassir R, et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res (2014) 74:3248-58. doi:10.1158/0008-5472.CAN-13-3514
32. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 70:741-51. doi:10.1158/0008-5472.CAN-09-2141
33. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 4:579-91. doi:10.1038/nrc1408
34. Vigneri P, Frasca F, Sciacca L, Frittitta L, Vigneri R. Obesity and cancer. Nutr Metab Cardiovasc Dis (2006) 16:1-7. doi:10.1016/j.numecd.2005.10.013
35. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer (2009) 16:1103-23. doi:10.1677/ERC-09-0087
36. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer (1992) 52:511-6. doi:10.1002/ijc.2910520402
37. Belfiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2008) 13:381-406. doi:10.1007/s10911-008-9099-z
38. Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 36(Suppl 2):S233-9. doi:10.2337/dcS13-2001
39. Willemse PP, van der Meer RW, Burggraaf J, van Elderen SG, de Kam ML, de Roos A, et al. Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy. Acta Oncol (2014) 53:351-60. doi:10.3109/0284186X.2013.819116
40. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 371:569-78. doi:10.1016/S0140-6736(08)60269-X
41. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer (2011) 18:R125-47. doi:10.1530/ERC-11-0074
42. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia (2010) 53:1743-53. doi:10.1007/s00125-010-1760-6
43. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets (2009) 10:923-36. doi:10.2174/138945009789577945
44. Singh P, Alex JM, Bast F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol (2014) 31:805. doi:10.1007/s12032-013-0805-3
45. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 8:915-28. doi:10.1038/nrc2536
46. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev (2014) 40:1096-105. doi:10.1016/j.ctrv.2014.07.004
47. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene (2011) 30(24):2730-40. doi:10.1038/onc.2010.640
48. Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne) (2014) 5:10. doi:10.3389/fendo.2014.00010
49. Bradley LM, Gierthy JF, Pentecost BT. Role of insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line. J Steroid Biochem Mol Biol (2008) 109:185-96. doi:10.1016/j.jsbmb.2007.10.006
50. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res (2000) 60:3175-82. Available from: http://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1363&context=oapubs
51. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, et al. Metastases of prostate cancer express estrogen receptor-beta. Urology (2004) 64:814-20. doi:10.1016/j.urology.2004.05.036
52. Bennesch MA, Picard D. Minireview: tipping the balance: ligand-independent activation of steroid receptors. Mol Endocrinol (2015) 29:349-63. doi:10.1210/me.2014-1315
53. Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signal (2012) 24:1515-21. doi:10.1016/j.cellsig.2012.03.012
54. Newton CJ, Buric R, Trapp T, Brockmeier S, Pagotto U, Stalla GK. The unliganded estrogen receptor (ER) transduces growth factor signals. J Steroid Biochem Mol Biol (1994) 48(5-6):481-6. doi:10.1016/0960-0760(94)90197-X
55. Ma ZQ, Santagati S, Patrone C, Pollio G, Vegeto E, Maggi A. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. Mol Endocrinol (1994) 8:910-8. doi:10.1210/me.8.7.910
56. Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Andò S, et al. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets (2008) 8:597-610. doi:10.2174/156800908786241104
57. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, et al. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol (2006) 191:605-12. doi:10.1677/joe.1.07016
58. Sisci D, Morelli C, Cascio S, Lanzino M, Garofalo C, Reiss K, et al. The estrogen receptor a: insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann Oncol (2007) 18:vi81-6. doi:10.1093/annonc/mdm232
59. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol (1997) 1:39-47. doi:10.1677/joe.0.1520039
60. Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, et al. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. Biochem Biophys Res Commun (2001) 288:685-9. doi:10.1006/bbrc.2001.5815
61. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem (1996) 271:1016-21. doi:10.1074/jbc.271.2.1016
62. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem (2000) 275:18447-53. doi:10.1074/jbc.M910345199
63. Gaben AM, Sabbah M, Redeuilh G, Bedin M, Mester J. Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer (2012) 12:291. doi:10.1186/1471-2407-12-291
64. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology (2000) 141(12):4503-11. doi:10.1210/endo.141.12.7836
65. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol (2011) 25:51628. doi:10.1210/me.2010-0373
66. Cascio S, Bartella V, Garofalo C, Russo A, Giordano A, Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem (2007) 282(6):3498-506. doi:10.1074/jbc.M606244200
67. Takeo C, Ikeda K, Horie-Inoue K, Inoue S. Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus. Endocr J (2009) 56(1):113-20. doi:10.1507/endocrj.K08E-220
68. Ramachandran C, Khatib Z, Petkarou A, Fort J, Fonseca HB, Melnick SJ, et al. Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol (2004) 67(1-2):19-28. doi:10.1023/B:NEON.0000021738.77612.1b
69. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat (2012) 132:61-73. doi:10.1007/s10549-011-1540-0
70. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor (IGF1R): implications for breast cancer treatment. Cancer Res (2012) 72:3372-80. doi:10.1158/0008-5472.CAN-12-0684
71. Genua M, Pandini G, Sisci D, Castoria G, Maggiolini M, Vigneri R, et al. Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. Cancer Res (2009) 69:7270-7.
72. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J (2000) 19(20):5406-17. doi:10.1093/emboj/19.20.5406
73. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J (2001) 21:6050-9. doi:10.1093/emboj/20.21.6050
74. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 104(5):719-30. doi:10.1016/S0092-8674(02)08100-X
75. Monnier D, Boutillier AL, Giraud P, Chiu R, Aunis D, Feltz P, et al. Insulin-like growth factor-I stimulates c-fos and c-jun transcription in PC12 cells. Mol Cell Endocrinol (1994) 104(2):139-45. doi:10.1016/0303-7207(94)90116-3
76. Linnerth NM, Baldwin M, Campbell C, Brown M, McGowan H, Moorehead RA. IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene (2005) 24(49):7310-9. doi:10.1038/sj.onc.1208882
77. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J Endocrinol (2010) 204:105-14. doi:10.1677/JOE-09-0242
78. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov (2011) 10:47-60. doi:10.1038/nrd3320
79. Pupo M, Vivacqua A, Perrotta I, Pisano A, Aquila S, Abonante S, et al. The nuclear localization signalis required for nuclear GPER translocation and function in breast cancer-associated fibroblasts (CAFs). Mol Cell Endocrinol (2013) 376:23-32. doi:10.1016/j.mce.2013.05.023
80. De Marco P, Romeo E, Vivacqua A, Malaguarnera R, Abonante S, Romeo F, et al. GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocr Relat Cancer (2014) 21:739-53. doi:10.1530/ERC-14-0245
81. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol (2002) 14:1649-60. doi:10.1210/mend.14.10.0532
82. Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, et al. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstet Gynecol Int (2013) 2013:472720. doi:10.1155/2013/472720
83. Goswami C, Kuhn J, Dina OA, Fernandez-Ballester G, Levine JD, FerrerMontiel A, et al. Estrogen destabilizes microtubules through an ion conductivity-independent TRPV1 pathway. J Neurochem (2011) 117:995-1008. doi:10.1111/j.1471-4159.2011.07270.x
84. Zucchetti AE, Barosso IR, Boaglio AC, Basiglio CL, Misczuk G, Larocca MC, et al. G protein coupled receptor30-adenylyl cyclase-protein kinase A pathway is involved in estradiol 17ss-d-glucuronide-induced cholestasis. Hepatology (2013) 59:1016-29. doi:10.1002/hep.26752
85. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science (2005) 11(307):1625-30. doi:10.1126/science.1106943
86. Tica AA, Dun EC, Tica OS, Gao X, Arterburn JB, Brailoiu GC, et al. G protein-coupled estrogen receptor 1-mediated effects in the rat myometrium. Am J Physiol Cell Physiol (2011) 301(5):C1262-9. doi:10.1152/ajpcell.00501.2010
87. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol (2008) 109:350-3. doi:10.1016/j.jsbmb.2008.03.006
88. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol (2010) 320:162-70. doi:10.1016/j.mce.2010.02.006
89. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counter selectivity. J Steroid Biochem Mol Biol (2011) 127:358-66. doi:10.1016/j.jsbmb.2011.07.002
90. Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, et al. MIBE acts as antagonist ligand of both estrogen receptor a and GPER in breast cancer cells. Breast Cancer Res (2012) 14:R12. doi:10.1186/bcr3096
91. Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, Maggiolini M. Recent advances in the rationale design of GPER ligands. Curr Med Chem (2012) 19:6199-206. doi:10.2174/092986712804485755
92. Santolla MF, De Francesco EM, Lappano R, Rosano C, Abonante S, Maggiolini M. Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Cell Signal (2014) 26:1466-75. doi:10.1016/j.cellsig.2014.03.011
93. O'Brien JE, Peterson TJ, Tong MH, Lee EJ, Pfaff LE, Hewitt SC, et al. Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements. J Biol Chem (2006) 281:26683-92. doi:10.1074/jbc.M601522200
94. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol (2006) 20(3):631-46. doi:10.1210/me.2005-0280
95. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology (2008) 8:3799-808. doi:10.1210/en.2008-0117
96. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol (2009) 308:32-8. doi:10.1016/j.mce.2009.03.026
97. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G1 in ovarian cancer cells. Cancer Res (2007) 67:1859-66. doi:10.1158/0008-5472.CAN-06-2909
98. Li Y, Chen Y, Zhu ZX, Liu XH, Yang L, Wan L, et al. 4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells. Toxicology (2013) 5(309):61-5. doi:10.1016/j.tox.2013.04.012
99. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J (2009) 28:523-32. doi:10.1038/emboj.2008.304
100. Vivacqua A, Romeo E, De Marco P, De Francesco EM, Abonante S, Maggiolini M. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat (2012) 133:1025-35. doi:10.1007/s10549-011-1901-8
101. De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S, et al. GPER mediates activation of HIF-1a/VEGF signaling by estrogens. Cancer Res (2014) 74:1-12. doi:10.1158/0008-5472.CAN-13-3590
102. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res (2010) 70:6036-46. doi:10.1158/0008-5472.CAN-10-0408
103. Luo H, Yang G, Yu T, Luo S, Wu C, Sun Y, et al. GPER-mediated proliferation and estradiol production in breast cancer associated fibroblasts. Endocr Relat Cancer (2014) 21:355-69. doi:10.1530/ERC-13-0237
104. Catalano S, Giordano C, Panza S, Chemi F, Bonofiglio D, Lanzino M, et al. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res Treat (2014) 146:273-85. doi:10.1007/s10549-014-3017-4
105. Mizukami Y. In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocr J (2010) 57:101-7. doi:10.1507/endocrj.K09E-332
106. Mårtensson UE, Salehi SA, Windahl S, Gomez MF, Swärd K, Daszkiewicz-Nilsson J, et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology (2009) 150:687-98. doi:10.1210/en.2008-0623
107. Liu S, Kilic G, Meyers MS, Navarro G, Wang Y, Oberholzer J, et al. Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia (2013) 56:370-81. doi:10.1007/s00125-012-2764-1
108. Balhuizen A, Kumar R, Amisten S, Lundquist I, Salehi A. Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell Endocrinol (2010) 320:16-24. doi:10.1016/j.mce.2010.01.030
109. Liu S, Le May C, Wong WP, Ward RD, Clegg DJ, Marcelli M, et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes (2009) 58:2292-302. doi:10.2337/db09-0257
110. Sharma G, Prossnitz ER. Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic β-Cells. Endocrinology (2013) 152:3030-9. doi:10.1210/en.2011-0091
111. Barton M. Position paper: the membrane estrogen receptor GPER-clues and questions. Steroids (2012) 10:935-42. doi:10.1016/j.steroids.2012.04.001
112. Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol (2014) 389:71-83. doi:10.1016/j.mce.2014.02.002
113. Borjesson AE, Windahl SH, Lagerquist MK, Engdahl C, Frenkel B, Moverare-Skrtic S, et al. Roles of transactivating functions1and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci U S A (2011) 108:6288-93. doi:10.1073/pnas.1100454108
114. Moverare-Skrtic S, Borjesson AE, Farman HH, Sjogren K, Windahl SH, Lagerquist MK, et al. The estrogen receptor antagonist ICI182, 780 can act both as an agonist and an inverse agonist when estrogen receptor alpha AF-2 is modified. Proc Natl Acad Sci U S A (2014) 111:1180-5. doi:10.1073/pnas.1322910111
115. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, et al. G protein coupled receptor 30 expression is up-regulated by EGF and TGF a in estrogen receptor alpha-positive cancer cells. Mol Endocrinol (2009) 23:1815-26. doi:10.1210/me.2009-0120
116. Recchia AG, De Francesco EM, Vivacqua A, Sisci D, Panno ML, Ando S, et al. The G protein-coupled receptor 30 is up-regulated by hypoxia inducible factor-1a (HIF-1a) in breast cancer cells and cardiomyocytes. J Biol Chem (2011) 286:10773-82. doi:10.1074/jbc.M110.172247
117. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, et al. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat (2010) 123:51-8. doi:10.1007/s10549-009-0631-7
118. Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res Treat (2014) 145:61-71. doi:10.1007/s10549-014-2936-4
119. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res (2010) 16:2505-11. doi:10.1158/1078-0432.CCR-09-2229
120. Rozengurt E. Mitogenic signaling pathways induced by G protein coupled receptors. J Cell Physiol (2007) 213:589-602. doi:10.1002/jcp.21246
121. De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene (2013) 6:678-88. doi:10.1038/onc.2012.97
122. Garrido P, Moran J, Alonso A, Gonzàlez S, Gonzàlez C. 17b-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology (2013) 154:1979-89. doi:10.1210/en.2012-1558
123. Alonso A, Fernàndez R, Moreno M, Ordònêz P, Gonzalez-Pardo H, Conejo NM, et al. Positive effects of 17b-estradiol on insulin sensitivity in aged ovariectomized female rats. J Gerontol A Biol Sci Med Sci (2006) 61:419-26. doi:10.1093/gerona/61.5.419